ClinicalTrials.gg
Status unknownNCT05211167Updated Jan 27, 2022

Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure

A Phase 3 interventional study of Human Erythropoiesis Injection (CHO cell) and Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell) in Kidney Failure, Chronic and Hemodialysis, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-27.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2021, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 114 studies in Kidney Failure, Chronic with a site in China — 28 open to participants now, 36 under way, 1 of them phase 3. Kidney Failure, Chronic · China.

Planned enrollment
26th of 83
300 · median 150
Started
2021
with 3 others
Phase 3
6 of 114
none open now
Registered
66th of 114
by date
Lead sponsor
3 of 114
Shenyang Sunshine Pharmaceutical Co., LTD.

Among the 114 studies in Kidney Failure, Chronic with a site in China, this one is the 26th largest by planned enrollment of the 83 interventional ones that give a count, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 66th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 114 studies in Kidney Failure, Chronic with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Kidney Failure, Chronic with a site in China, or all of them as a file.
02

Study summary

To verify the efficacy of recombinant erythropoiesis stimulating protein injection (CHO cell) in hemodialysis patients with chronic renal failure anemia maintenance treatment is not inferior to yibio.

Read the detailed description

In this phase 3, open label, active comparator parallel controlled study, patients were randomly assigned to two study groups: one active comparator control group (Human Erythropoietin Injection , maintaining the same dose and frequency administrated in the sceening period ), and experimental groups (50μg, once every two weeks). All the patients were administered intravenously for 32 weeks and were evaluated the efficacy, safety and pharmacokinetic characteristics. During the whole study period, dosage adjustment was not allowed in the first 4 weeks, while in the remaining trial period dosage adjustment was allowed once every two weeks if necessary.

03

Conditions studied

  • Kidney Failure, Chronic
  • Hemodialysis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteer as a subject must understand the study procedure and sign the form;
  • 18 years old ≤ age ≤ 75 years old when sign ICF, gender is not limited;
  • Patients diagnosed with chronic renal failure anemia were receiving maintenance hemodialysis for at least 3 months and 2-3 times a week; The dialysis frequency was stable and there was no change in the dialysis plan throughout the study period;
  • Before enrollment, patient being treated short-acting EPO stabilization therapy for at least 12 weeks, the average concentration of in the screening period is in the range of 100\~120 g/L (including both ends), and the difference is less than 10g/L;
  • Iron status and dialysis status were evaluated within 4 weeks before enrollment to meet the following requirements:

Transferrin saturation (TSAT) ≥20% and serum ferritin (SF) ≥200 μg/L; Dialysis parameters: urea clearance index spKt/V≥1.2;

  • Subjects agree to use reliable by themselves and their spouses from the screening period to within 3 months after the end of the study;

Exclusion criteria

Exclusion Criteria:

  • Allergic to the drug or any ingredient in the investigational drug or has had a severe allergic reaction to the drug in the past;
  • Except of renal anemia, there are other diseases that cause chronic anemia (such as sickle cell anemia, myelodysplastic syndrome, hematological , myeloma, hemolytic anemia, pure red blood cell aplastic anemia), blood systemic disease or coagulopathy;
  • Patients who have received or plan to have a kidney transplant during the study period, or who plan to have other surgical procedures during the study period (mainly major surgeries, except those with low blood loss that do not affect concentration);
  • Patients with acute or chronic blood loss (such as upper gastrointestinal bleeding, etc.) within 3 months prior to enrollment were excluded from the scope of hemorrhage caused by minor surgeries such as temporary vascular access required by clinical medical procedures;
  • Patiernts who was suffering from malignant hypertension or poor control of blood pressure (systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg);
  • The following conditions (including but not limited to) occurred in the laboratory examination during the screening period, and the investigator judged that the participants were not eligible for inclusion: a) Patients who were positive for , anti-, anti-, and Treponema pallidum antibodies; b) The or alanine aminotransferase is greater than 3 times the ; c) Serum albumin \< 35g/L;
  • Patiernts who was suffering from severe secondary hyperparathyroidism (sustained blood iPTH/PTH >1000 ng/L);
  • Patients with previous thromboembolic disease (excluding luminal infarction), history of severe hematopoietic system, and high clotting tendency;
  • Patiernts with severe cardiovascular and cerebrovascular disease, severe or unstable coronary artery disease, heart failure ( class III or IV), temporary vascular access, or myocardial infarction or stroke within 3 months before enrollment;
  • A history of malignant neoplasms, except for: basal cell or squamous cell carcinoma of the skin determined to be cured or no recurrence within 5 years, with radical excision, or carcinoma in situ at any site;
  • The researchers identified those with severe infectious disease or chronic, uncontrolled inflammation within the first four weeks of enrollment;
  • All epilepsy or epilepsy history except of childhood febrile seizures, post-traumatic or abstinence single seizures;
  • Those who have received androgen therapy or who have received blood transfusion therapy within the past 8 weeks before enrollment;
  • Patients who had a pacemaker for more than 5 years; If no more than 5 years of cardiac pacemaker working status assessment and test unqualified;
  • 3 months as a subject to participate in other new drug clinical trials or to the group when the withdrawal time is shorter than the five half-life of the test drug (whichever is the longest of the two);
  • Subjects were in the middle of pregnancy or lactation at the time of enrollment;
  • Alcohol, drug or drug addicts;
  • Other conditions that may not be suitable for the study as determined by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Group A

    Intravenous administration, maintaining the same dose and frequency administrated in the sceening period, for 32 weeks

    Drug: Human Erythropoiesis Injection (CHO cell)

  • Experimental
    Group B

    Intravenous administration,50μg, once every two weeks, for 32 weeks

    Drug: Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)

Interventions

06

What researchers measure

Primary outcomes

  1. hemoglobin concentration

    the amount of change in mean Hb concentration compared with baseline Hb concentration during the evaluation period

    Time frame: 25th-32nd week

Secondary outcomes

  1. maintenance rate

    the proportion of subjects whose average Hb concentration remained within the target range during the evaluation period

    Time frame: 25th-32nd week

  2. proportion of subjects

    the proportion of subjects whose range of dose adjustments decreased or increased by 25% still did not reach 100-120 g/L (both ends)

    Time frame: for 32 weeks

  3. proportion of times

    the proportion of times the measured Hb concentration remains within the target range during the subject evaluation period

    Time frame: 25th-32nd week

  4. average weekly dose

    the average weekly dose of the drug during the evaluation period

    Time frame: 25th-32nd week

  5. average hemoglobin concentration

    the mean Hb concentration during the evaluation period

    Time frame: 25th-32nd week

  6. mean reticulocyte count

    changes in mean values of reticulocyte compared to baseline values during the evaluation period

    Time frame: 25th-32nd week

  7. mean red blood cell count

    changes in mean values of red blood cell count compared to baseline values during the evaluation period

    Time frame: 25th-32nd week

  8. adverse events

    the type, proportion and severity of adverse events

    Time frame: for 32 weeks

  9. number of dose adjustments

    the number of dose adjustments used by the subject during the treatment and evaluation period

    Time frame: for 32 weeks

  10. the ratio of subjects who are adjusted

    the ratio of subjects who are adjusted during the treatment and evaluation period

    Time frame: for 32 weeks

  11. incidence of Human Erythropoietin antibodies and anti-rESP antibodies

    incidence of Human Erythropoietin antibodies and anti-rESP antibodies

    Time frame: for 32 weeks

  12. Maximum Plasma Concentration (Cmax)

    the Cmax of rESP in patients with long-term medication

    Time frame: for 32 weeks

  13. Area Under the Curve (AUC)

    the AUC of rESP in patients with long-term medication

    Time frame: for 32 weeks

07

Study locations

1 of 1 sites recruiting
  • Chinese PLA General Hospital
    Beijing, Beijing 200443, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Jun 2023, 23 months after the start.

Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's planned 23 months is below that.

Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2022
First posted
Jan 27, 2022
StartActual
Jul 1, 2021
Primary completionEst.
Jun 30, 2023
CompletionEst.
Dec 30, 2023
Last update
Jan 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05211167
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Jul 1, 2021
Primary completion
Jun 30, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
Jan 27, 2022

Study contacts

Gang Tong, MD
Contact
tonggang@3sbio.com
021-60970099
XiangMei Chen, MD
principal investigator · Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHO cell

Start the discussion